Tanvex BioPharma (Taiwan) Insiders
| 6541 Stock | TWD 72.00 0.50 0.69% |
Tanvex BioPharma employs about 23 people. The company is managed by 21 executives with a total tenure of roughly 119 years, averaging almost 5.0 years of service per executive, having 1.1 employees per reported executive. Recap of Tanvex BioPharma's management performance can provide insight into the venture performance.
| Lin Chen CEO Chief Executive Officer, Chief Financial Officer, Head of Finance, Director |
| Allen Chao Chairman Chairman of the Board, Chief Executive Officer, General Manager |
Tanvex |
Tanvex BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2041) % which means that it has lost $0.2041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.603) %, meaning that it generated substantial loss on money invested by shareholders. Tanvex BioPharma's management efficiency ratios could be used to measure how well Tanvex BioPharma manages its routine affairs as well as how well it operates its assets and liabilities.Tanvex BioPharma Workforce Comparison
Tanvex BioPharma is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 170. Tanvex BioPharma retains roughly 23.0 in number of employees claiming about 14% of stocks in Biotechnology industry.
Tanvex BioPharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Tanvex BioPharma Price Series Summation is a cross summation of Tanvex BioPharma price series and its benchmark/peer.
Tanvex BioPharma Notable Stakeholders
A Tanvex BioPharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tanvex BioPharma often face trade-offs trying to please all of them. Tanvex BioPharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tanvex BioPharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lin Chen | Chief Executive Officer, Chief Financial Officer, Head of Finance, Director | Profile | |
| Allen Chao | Chairman of the Board, Chief Executive Officer, General Manager | Profile | |
| David Hsia | Chief Technology Officer, Director | Profile | |
| Val Chen | Director Officer | Profile | |
| Helena Makagiansar | Deputy General Manager-LJB Production Development | Profile | |
| Yongjian Wu | Deputy General Manager-LJB Research & Development | Profile | |
| LungYeh Cho | Director | Profile | |
| Dilip Joshi | VP US | Profile | |
| LeeChiou Chang | Independent Director | Profile | |
| FACP FACP | Pres Chairman | Profile | |
| Lily Yuan | Site LJB | Profile | |
| K Lin | Co CFO | Profile | |
| Linda Grillo | Director Marketing | Profile | |
| Zheng Xia | Chief Officer | Profile | |
| Mike Parker | Senior Deputy General Manager-Technology | Profile | |
| ChiChuan Chen | Chairman of the Board | Profile | |
| Yun Yen | Director | Profile | |
| Kaiwen Yang | Deputy General Manager-LJB Production | Profile | |
| Tamon Tseng | Director | Profile | |
| Chuan Shih | Independent Director | Profile | |
| JinPau Tsai | Independent Director | Profile |
About Tanvex BioPharma Management Performance
The success or failure of an entity such as Tanvex BioPharma often depends on how effective the management is. Tanvex BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tanvex management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tanvex management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. TANVEX BIOPHARMA is traded on Taiwan Stock Exchange in Taiwan.
Please note, the imprecision that can be found in Tanvex BioPharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tanvex BioPharma. Check Tanvex BioPharma's Beneish M Score to see the likelihood of Tanvex BioPharma's management manipulating its earnings.
Tanvex BioPharma Workforce Analysis
Traditionally, organizations such as Tanvex BioPharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tanvex BioPharma within its industry.Tanvex BioPharma Manpower Efficiency
Return on Tanvex BioPharma Manpower
| Revenue Per Employee | 235K | |
| Revenue Per Executive | 257.4K | |
| Net Loss Per Employee | 67.1M | |
| Net Loss Per Executive | 73.5M |
Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.